Perrigo Company plc Purchase Obligation
Perrigo Company plc (PRGO) had Purchase Obligation of $275.20 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Commitment and Contingencies
us-gaap:PurchaseObligation · last filed 2026-02-26
- 2025-12-31: Purchase Obligation $275.20M.
- 2024-12-31: Purchase Obligation $316.80M.
- 2023-12-31: Purchase Obligation $355.30M.
- 2022-12-31: Purchase Obligation $407.90M.
| Period end | Purchase Obligation |
|---|---|
| 2025-12-31 | $275.20M 10-K · filed 2026-02-26 |
| 2024-12-31 | $316.80M 10-K · filed 2025-02-28 |
| 2023-12-31 | $355.30M 10-K · filed 2024-02-27 |
| 2022-12-31 | $407.90M 10-K · filed 2023-02-28 |
| 2021-12-31 | $865.60M 10-K · filed 2022-03-01 |
| 2020-12-31 | $1.20B 10-K · filed 2021-03-01 |
| 2019-12-31 | $845.90M 10-K · filed 2020-02-27 |
| 2018-12-31 | $758.30M 10-K · filed 2019-02-27 |
| 2017-12-31 | $771.00M 10-K · filed 2018-03-01 |
| 2016-12-31 | $791.60M 10-K · filed 2017-05-22 |
| 2015-12-31 | $403.70M 10-KT · filed 2016-02-25 |
| 2015-06-27 | $429.90M 10-K · filed 2015-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |